Contrast agent holds promise for Breast Cancer imaging
Data presented at the World Molecular Imaging Congress by Imagion Biosystems Limited reports the study of MagSense utility as a potential MRI contrast agent.
The data demonstrated the possible use of nano-particles for detecting HER2 breast cancer cells. It is the first study reported by Imagion that demonstrates the use of anti-HER2 nanoparticles used in Imagion's MagSense technology.
This platform provides specific targeting of cancerous cells, which may also have potential as an MR imaging contrast agent.
The study shows that the MagSense nanoparticles may be equally effective as a multi-modal molecular imaging agent, generating detectable signals in two different imaging methods -- super magnetic relaxometry (SPMR) and magnetic resonance imaging (MRI).
"This study provides further evidence and insight into the effectiveness of our nano-particles and their ability to specifically bind to target tissue, where they then act as a magnetic tag or beacon and a non-invasive imaging tool," said Bob Proulx, CEO of Imagion Biosystems.
Imagion's proprietary MagSense technology works through the use of tiny bio-safe nano-particles coated with tumor targeting antibodies to tag to the cancer cells. The sensors are able to detect the particles which have become attached to cancer cells. This then acts like a magnetic beacon as bone and normal tissue are transparent to the detection platform.
In the MRI setting, contrast agents are used to enhance the image and improve resolution. However, at present, contrast agents do not provide functional imaging utility.
The MagSense nanoparticles detectable by SPMR, can also be used as a contrast agent is able to enhance an MR image of specific tissue. This will create an opportunity for Imagion to work with the large installed base of existing MRI machines.
"Our Toxicology studies have already demonstrated that our nanoparticles should be safe for use in humans and we remain focused on the completion of our first-in-human studies and the well-defined shortest path to commercialization. However, we are encouraged by these early results and plan to embark on further studies, to explore how our technology could be optimally positioned alongside existing clinical practices to enhance its commercial potential." Said Mr Proulx.
The poster presented by Dr Marie Zhang, VP of Research and Pre-Clinical Development at Imagion BIosystems can be found here.